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Abstract
Background: In 1988 the World Health Assembly adopted the goal to eradicate poliomyelitis by
routine immunization using Oral Polio Vaccine (OPV). On 21 June 2002 the WHO European
Region was declared polio-free. In 2008 poliomyelitis is still endemic in 4 countries (Nigeria, India,
Pakistan, and Afghanistan), where 1201 new cases were registered in 2007; 107 sporadic cases
were also notified in countries where poliovirus is not endemic. The aim of this work was to verify
the level of antipoliomyelitis immunity status in children and adolescents in the Apulia region (south
of Italy), which may be considered a border region due to its position.
Methods: 704 blood specimens from a convenience sample were collected in six laboratories. The
age of subjects enrolled was 0–15 years. The immunity against poliomyelitis was evaluated by
neutralizing antibody titration in tissue culture microplates.
Results: Seropositivity (neutralising antibodies titre ≥ 8) for polioviruses 1, 2 and 3 was detected
in 100%, 99.8% and 99.4% of collected sera. Antibody titres were not lower in subjects who
received either four doses of inactivated polio vaccine (IPV) or a sequential schedule consisting of
two doses of IPV and two of oral polio vaccine than in subjects who received four doses of OPV.
Conclusion: These results confirmed current data of vaccine coverage for poliomyelitis: during
the last ten years in Apulia, the coverage in 24 months old children was more than 90%. The high
level of immunization found confirms the effectiveness both of the sequential schedule IPV-OPV
and of the schedule all-IPV. Apulia region has to face daily arrivals of refugees and remains subject
to the risk of the importation of poliovirus from endemic areas. Surveys aimed at determining anti-
polio immunity in subpopulations as well as in the general population should be carried out.
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Background
In 1988 the World Health Assembly adopted the goal to
eradicate poliomyelitis by routine immunization using
Oral Polio Vaccine (OPV) at birth followed by three doses
at 6, 10 and 14 weeks supplemented by surveillance for
acute flaccid paralysis (AFP), national immunization days
(NIDs) and mopping-up immunization campaigns [1].
In developing countries, during the National Immuniza-
tion Days, as recommended by the World Health Organi-
zation (WHO), two doses of OPV were given to all
children under the age of five irrespective of their vaccina-
tion status [2]. The final stages of this program require a
mopping-up activity, that is a door-to-door search for sub-
jects to be immunized. This operation turns out to be par-
ticularly effective in those areas characterized by poor
health infrastructure and immunization services [3-6].
The WHO European Region included in the Expanded
Program of Immunization the goal of wild poliovirus glo-
bal eradication [7,8]. In the European region, by the end
of 1996, all poliomyelitis endemic countries had con-
ducted NIDs (operation MEGACAR) because of a large
outbreak of 154 cases of paralytic disease in Chechnya
and suboptimal routine immunization coverage in other
countries. In the autumn of 1996 Albania also started a
mass campaign with OPV to control outbreaks [9]. In
1998 only Turkey reported 23 cases of AFP due to wild
virus. Europe's last case of indigenous wild poliomyelitis
occurred in eastern Turkey in 1998, when a two-year-old
unvaccinated boy was paralysed by the virus. On 21 June
2002 the WHO European Region was declared polio-free.
In 2008 poliomyelitis is still endemic in 4 countries
(Nigeria, India, Pakistan, and Afghanistan), where 1201
new cases were registered in 2007; 107 sporadic cases were
also notified in countries where poliovirus is not endemic
[10].
The WHO Polio Eradication Strategic Plan for 2004–2008
recommends the discontinuation of vaccination with
OPV after global eradication of wild poliovirus [11] and
the use of Inactivated Poliovirus Vaccine (IPV). IPV is con-
sidered to be safer than OPV because IPV is not associated
with the rare risk of vaccine-associated paralytic poliomy-
elitis (VAPP) [12,13] or with the emergence of neuroviru-
lent vaccine-derived poliovirus [14-18]. Some
industrialized countries, such as Sweden, Finland and The
Netherlands, have chosen to use IPV instead of OPV [19]
in 2003. In the United States an all-IPV schedule has been
adopted since 2000 and the use of this schedule is associ-
ated with the elimination of VAPP in USA [20].
In Italy the last two cases of poliomyelitis due to transmis-
sion of indigenous wild poliovirus occurred in 1982,
when the virus was detected in subjects who had not been
immunized by the age of 1 year, and the last imported
case was in 1988 [21]. Vaccination against poliomyelitis
with OPV was introduced in the compulsory immuniza-
tion schedule in 1966: the vaccination schedule provided
for three-dose administration of OPV at 3, 5 and 11
months of age and a booster dose at 3 years-old.
Since 1999, a sequential schedule consisting of two doses
of inactivated polio vaccine (at 3 and 5 months) and two
of oral polio vaccine (at 11 months and 3 years of age)
was adopted; in July 2002 a schedule consisting of four
doses of IPV was adopted [22]. In 2005, National Vaccine
Plan 2005–2007 introduced a schedule consisting of four
doses of IPV at 3, 5, 11 months and 4–5 years-old [23].
In 2001 in Italy a combined DTPa-HBV-IPV/Hib vaccine
containing diphtheria (D), tetanus (T), acellular pertussis
(Pa), hepatitis B (HBV) and types 1, 2 and 3 inactivated
polioviruses (IPV) mixed with a conjugated Haemophilus
influenzae type b (Hib) vaccine, administered according
to a 3, 5 and 11–13 month vaccination schedule, was
introduced. The availability of hexavalent vaccination
should contribute to increase the vaccination coverage of
the population [24] that has reached or exceeded 95%
[25].
As the disease does not respect national borders or conti-
nental boundaries, regions and areas where eradication
has been achieved must continue to ensure high levels of
immunization coverage to prevent re-establishment of
poliovirus if it is re-introduced from other countries
through international travellers, migrant populations
from conflict areas or population sub-groups who refuse
vaccination.
Since 2002 Italy has been declared a polio-free country
but the risk of poliovirus reintroduction persists because
of immigration. Several seroepidemiological studies per-
formed in the past, the last-one conducted during 1999,
put in evidence unsatisfactory antibody titres in an impor-
tant proportion of young-adults, specially against poliovi-
rus 3 [26,27]. Despite the massive exodus of people from
East-Europe during 1990's and the large outbreak which
occurred in Albania in 1996, no imported cases have been
reported in the latest period because of the good level of
coverage for polio in these populations [28]. As in other
countries, since 1997 the surveillance system of all AFP
cases has been set up and, at the moment, it maintains a
good level of sensibility [29].
The aim of this work is to estimate the immunological sta-
tus against poliovirus in children and adolescents in
Apulia, after almost ten years after the last study con-
ducted [26].BMC Infectious Diseases 2008, 8:150 http://www.biomedcentral.com/1471-2334/8/150
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Methods
Samples collection
During 2007, a seroepidemiological survey was con-
ducted on blood samples collected from children and
adolescents from 3 months to 15 years old. Enrolled sub-
jects represented a convenience sample of the population
applying to 6 laboratories located in five of the six Prov-
inces of the Region (2 located in the Province of Bari, 1 in
the Province of Brindisi, 1 in the Province of Foggia, 1 in
the Province of Lecce; no laboratory in the Province of
Taranto), for diagnostic and check up testing.
According to the present Italian Data Protection Act, infor-
mations about initials, sex and year of birth of enrolled
subjects were collected; so it was impossible to assess vac-
cination status by card or history. Because of Data Protec-
tion Act was respected, ethical approval was not required
for this study.
Serology
Blood samples obtained from the laboratories were taken
to the WHO Sub-National Polio referred Reference Labo-
ratory in Bari and the sera stored at -20°C.
The immunity to poliovirus was measured by determining
the ability of a human serum sample to neutralize the
infectivity and the cytopathic effect (CPE) on cell cultures
in vitro of each of the three types of poliovirus. The neu-
tralization test in microtitre plates was performed accord-
ing to the guidelines for WHO/EPI collaborative studies
on poliomyelitis [30]. Serial two-fold dilution of inacti-
vated sera (from 1:8 to 1:1024) were incubated in dupli-
cate with 100 TCID50/0.025 ml challenge virus
suspension of each of the three reference Sabin strains
(Poliovirus type 1/Mahoney strain, Poliovirus type 2/
MEF-1 strain and Poliovirus type 3/Saukett strain). After
incubation for 3 hours at 36°C, 5% CO2, to each well with
virus-serum mixture a human heteroploid Hep-2 cell sus-
pension (1–2 × 104cells/0,1 ml; MEM Earle's salts 10%
FBS; 37°C, 5% CO2) was added. The virus titration of
each strain and cell controls were added to test and incu-
bated at 36°C for five days; the appearance of CPE was
examined with an inverted microscope.
Using the Karber formula, neutralizing antibody titre
(normally expressed as reciprocal) was the highest dilu-
tion of serum which protects 50% of the cultures against
100TCD50 of challenge virus, inhibiting the CPE. Titres ≥
1:8 were considered positive, as recommended by WHO/
EPI. Titres were computed as geometrical means (GMTs).
Statistical analysis
Contingence tables and χ2 values were used to assess dif-
ferences in the immunization rates among age groups and
to evaluate the association between antibody titres, age at
vaccination and the vaccine schedule used for immuniza-
tion. A value of p < 0.05 was considered as significant. Epi-
Info 6.00 (public domain software-CDC Atlanta, Georgia;
WHO Geneva) was used for statistical analysis.
Results
704 blood samples from children and adolescents aged 3
months-15 years were collected during 2007. 52.4%
(369) of the subjects were male and 47.6% (335) were
female. Median age was 6.6 years; there was no statically
significant difference by age between genders (p > 0,05).
Table 1 shows the distribution of samples by sex and age
groups. The most represented age groups were the ones in
the ranges 6–10 years and 3–5 years. The subjects were
from different geographical areas: 33.2% from the Prov-
ince of Bari, 29.8% from the Province of BAT (Barletta,
Andria, Trani), 27.7% from the Province of Lecce, 8.3%
from the Province of Foggia and 1% from the Province of
Brindisi.
An antibody titre ≥ 1:8 was found in 704 subjects (100%)
for poliovirus type 1 (Figure 1), in 703 subjects (99.8%)
for poliovirus type 2 (Figure 2) and in 700 subjects
(99.4%) for poliovirus type 3 (Figure 3). The protection
rate for all poliovirus types was 100% in all age group,
whereas the protection rate for poliovirus type 2 was
98.6% and for poliovirus type 3 was 95% in the subjects
< 1 year-old.
By dividing the antibody titres into two ranges (low: 8–32;
high: 64 – > 256) the number of subjects with titres 64 –
> 256 was higher than that of subjects with titres 8–32 in
all age groups and for all three types of polioviruses (for
poliovirus type 1: χ2 = 42.6; p < 0.001-for poliovirus type
2: χ2 = 27.6; p < 0.001-for poliovirus type 3: χ2 = 59.8; p <
0.001).
Antibody titres 8–32 for poliovirus type 1 were associated
with low titres for poliovirus type 2 (OR = 37.3; 95% CI:
10.5–133.1; χ2 = 74.95; p < 0.001) and for poliovirus type
3 (OR = 20.6; 95% CI: 6.3–67.5; χ2 = 47.6; p < 0.001).
Table 1: Distribution of samples by sex and age group
Male Female Total
Age group N%N%N%
< 1 year 44 11,9 29 8,7 73 10,4
1 year 23 6,2 24 7,2 47 6,7
2 years 25 6,8 18 5,4 43 6,1
3–5 years 81 21,9 77 23,0 158 22,4
6–10 years 116 31,4 117 34,9 233 33,1
11–12 years 39 10,6 31 9,3 70 9,9
13–15 years 41 11,1 39 11,6 80 11,4
Total 369 335 704BMC Infectious Diseases 2008, 8:150 http://www.biomedcentral.com/1471-2334/8/150
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Antibody titres against Poliovirus Type 1 Figure 1
Antibody titres against Poliovirus Type 1. Distribution by age.
Antibody titres against Poliovirus Type 2 Figure 2
Antibody titres against Poliovirus Type 2. Distribution by age.BMC Infectious Diseases 2008, 8:150 http://www.biomedcentral.com/1471-2334/8/150
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Antibody titres 8–32 for poliovirus type 2 were also asso-
ciated with low titres for poliovirus type 3 (OR = 22.6;
95% CI: 8.3–61.3; χ2 = 71.9; p < 0.001).
The age < 1 year was associated with antibody titres 8–32
for all three types of polioviruses (for poliovirus 1: OR =
19.3; 95% CI: 5.6–65.8; χ2 = 47.6; p < 0.001-for poliovirus
2: OR = 7.6; 95% CI: 2.9–20.0; χ2 = 23.0; p < 0.001-for
poliovirus 3: OR = 8.8; 95% CI: 4.4–17.7; χ2 = 51.0; p <
0.001).
Antibody titres higher than 8–32 for all three types of
polioviruses were detected in subjects aged > 1 year who
most likely received a vaccination schedule providing
three-dose administration, as all-IPV schedule (aged 1–2
years), as sequential schedule (aged 3–8 years) or an all-
OPV schedule (aged 9–15 years).
Discussion
The results of this survey showed a good level of immu-
nity against polioviruses 1, 2, 3 in Apulian children and
adolescents and this agrees with other serological surveys
performed in some Italian regions in the last decade [31-
34].
The lowest antibodies titres were detected in infants (age
< 1 year) who could not complete the primary vaccination
schedule. Antibodies titres against poliovirus 3 were >
95%, showing an improvement on the last studies in
which neutralizing antibodies against poliovirus type 1, 2
and 3 were detected in 97.6%, 95.8% and 70% of samples
respectively, and 3/1000 (0.3%) subjects were simultane-
ously seronegative to the three types [26,27].
These results confirmed current data of vaccine coverage
for poliomyelitis: during the last ten years in Apulia, the
coverage in 24 months old children was more than 90%
[25].
Even if in this study we did not assess immunization sta-
tus diretly and than we did not know if enrolled subjects
received one, two or three doses of vaccine or any, the
high level of immunization found could confirm the
effectiveness both of the sequential schedule IPV-OPV and
of the schedule all-IPV [16]. Our study shows strong evi-
dence that the changeover from an all-OPV schedule to
one containing all-IPV was not associated with a negative
impact on immunization coverage. In fact, receiving all-
IPV or a sequential vaccination schedule was not associ-
ated with lower antibodies titres.
As vaccine induced immunity declines with age, priority
in our country is to sustain high routine immunization
coverage and to emphasize a timely completion of pri-
mary immunization in accordance with the vaccine sched-
ule.
Antibody titres against Poliovirus Type 3 Figure 3
Antibody titres against Poliovirus Type 3. Distribution by age.BMC Infectious Diseases 2008, 8:150 http://www.biomedcentral.com/1471-2334/8/150
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A limitation of this study concerns sample enrollement:
subjects who go to a laboratory are likely receiving medi-
cal care by definition, and might be more likely to be vac-
cinated than those who did not go to a laboratory.
We can not exclude the existence of low-immunity pock-
ets in the population that were not detected in our study.
Surveys aimed at determining anti-polio immunity in
subpopulations as well as in the general population
should be carried out; the presence of population groups
with suboptimal coverage can alter the herd immunity
protection.
Conclusion
The Apulia region, which may be considered a border
region due to its position, has to face daily arrivals of ref-
ugees and remains subject to the risk of the importation of
poliovirus from endemic areas. Moreover, prisoners could
be at risk for a not-enough coverage.
Since Italy has obtained the certification of a "polio-free"
country, it is very important to prevent any possible risk of
introducing the wild polioviruses. This goal will be
reached by improving three strategies: the Acute Flaccid
Paralysis active surveillance system, research on environ-
mental wild polioviruses and by measures aiming at eval-
uating and improving vaccine coverage against
poliomyelitis in children and immigrants.
As considered by Fine PE et al. in 2004, now that the glo-
bal eradication of wild poliovirus is almost within sight,
planning for the post-certification era is becoming a prior-
ity issue. It is agreed that a stockpile of appropriate polio
vaccines will need to be established, and a surveillance
and response capacity will need to be maintained, in
order to protect the world against any possible future out-
breaks attributable either to the persistence of wild polio-
virus or vaccine-derived polioviruses or to the
unintentional or intentional release of poliovirus from a
laboratory or vaccine store. Although it has been sug-
gested that the stockpile should consist of monovalent
oral poliovirus vaccine (mOPV), many questions remain
concerning its nature, financing, management and use, in
particular because of uncertainties over future national
vaccination policies and over the availability of different
vaccines after the certification of wild poliovirus eradica-
tion. There are further uncertainties concerning the possi-
ble role and efficacy of IPV used in outbreak control in
low-hygiene settings, the potential for rapid geographical
spread of polioviruses should an outbreak occur after cer-
tification, and the risks inherent in introducing additional
OPV viruses into populations in which the vaccine cover-
age and prevalence of immunity have declined, and which
may thus favour the spread of VDPVs. Given these impor-
tant gaps in knowledge, no country should discontinue
polio vaccination until a coordinated policy for the post-
certification era has been developed and the recom-
mended measures have been put in place [35].
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